Loading data for INO — first visit, this takes a few seconds.

알림

Inovio Pharmaceuticals In... (INO)

NasdaqCM: INO · 실시간 가격 · USD

1.20

+0.05 (4.35%)

종가 기준: Aug 18, 2026, 3:59 PM

1.19

-0.83%

프리마켓: 8:04 AM

4.35% (1D)

매수호가	1.01
시가총액	123.99M
매출 (ttm)	n/a
순이익 (ttm)	-67.43M
베타	1.51
EPS (ttm)	-1.03
P/E (ttm)	n/a
선행 P/E	-2.73
P/B (ttm)	28.57
P/S (ttm)	n/a
Earnings Date	Nov 10, 2026

매도호가	1.35
거래량	4,719,596
평균 거래량 (20일)	3,072,477
시가	1.14
전일 종가	1.15
일중 범위	1.07 - 1.22
52주 범위	0.56 - 2.98
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

INO 소개

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The com...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 8, 1998

직원 수 112

상장 거래소 NasdaqCM

티커 INO

웹사이트 https://www.inovio.com

전체 기업 정보

재무 실적

2025년 Inovio Pharmaceuticals의 매출은 65.34K로, 전년 217.76K 대비 -69.99% 감소했습니다. 순이익은 -84.95M로, -20.8% 감소했습니다.

재무제표

어닝 서프라이즈

Inovio Pharmaceuticals가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.

EPS -0.24 예상치 하회 0.00, 및 60.66% 전년 대비 성장.

다음 실적 발표

Inovio Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 10, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · GuruFocus.com

Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...

Inovio reports a narrowed net loss and strong progress toward a potential INO-3107 launch, while securing funding through late Q1 2027.

6일 전 · Moby

Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call

6일 전 · MarketBeat

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigati...

2개월 전 · MarketBeat

Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young ...

2개월 전 · Stocktwits

INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial

The study showed that the treatment helped reverse precancerous changes in the cervix and clear the high-risk HPV virus that causes them in many patients.

2 페이지 중 1